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AbstrACt
Objectives Studies exploring vaccination rates among 
haematopoietic stem cell transplant (HSCT) recipients 
have focused on physician factors that limit uptake. 
Understanding the patient factors that determine 
vaccination intention is crucial to delivering a successful 
vaccination programme. Using a modiied health belief 
model (mHBM), we conducted a cross-sectional survey 
with the objective of exploring the sociodemographic 
and psychological factors that determined autologous 
and allogeneic HSCT recipients’ intention to receive the 
seasonal inactivated inluenza vaccine (SIIV) during the 
2015–2016 inluenza season.
setting The setting of our study was three tertiary 
level, UK National Health Service (NHS) autologous and 
allogeneic HSCT centres.
Participants Eligible patients were aged 16 years or 
over and recipients of autologous or allogeneic HSCT for 
any disease indication, with no absolute contraindication 
to receiving the SIIV during the next inluenza season, 
and having not received the SIIV since transplant. 93 
participants from 3 UK NHS HSCT centres completed an 
anonymous study-speciic questionnaire. 78.5% were 
recipients of allogeneic and 21.5% autologous HSCT.
results 23.7% of participants expressed low intent to 
receive the SIIV. Patients aged over 65 (OR 0.02, 95% CI 
0.01 to 0.57, p=0.02) and those who had not received the 
SIIV prior to HSCT (OR 0.04, 95% CI 0.02 to 0.56, p=0.02) 
were less likely to have high intent. A multivariate logistic 
regression model incorporating constructs of the mHBM 
was statistically signiicant (p<0.001) and explained 
74.7% of variation in SIIV intention. More patients felt 
that a recommendation from their HSCT team than their 
general practitioner would prompt them to receive the 
SIIV, and this was most pronounced in those who had low 
intent.
Conclusions The mHBM may provide a useful structure 
for addressing low vaccine intent among HSCT recipients 
and further interventional studies are warranted. We would 
encourage HSCT and general practitioners to discuss SIIV 
intention as a routine part of care.
IntrOduCtIOn   
Innate and adaptive immune responses are 
impaired for months to years following autol-
ogous and allogeneic haematopoietic stem 
cell transplant (HSCT). Immune impairment 
following autologous HSCT is secondary to 
the administration of immunosuppressive 
conditioning regimens. In the setting of allo-
geneic HSCT, chronic graft versus host disease 
(GvHD) may also contribute to immune 
impairment and dysfunction through thymic 
strengths and limitations of this study
 Ź The study questionnaire was based on the estab-
lished theoretical framework of the health belief 
model, and questions were speciic with regard to 
vaccine and 2015–2016 season.
 Ź Participants from three geographically dispersed 
study sites completed anonymous questionnaires
 Ź The study explored intention to receive the inactivat-
ed inluenza vaccine during the 2015–2016 inluen-
za season. Uptake was not assessed and may differ 
from intention rates.
 Ź The number of enrolled participants expressing low 
vaccination intent was small at 22 (23.7%) and this 
may bias our data.
 Ź The study did not include a qualitative component 
and there may be additional determinants of inlu-
enza vaccine intention not captured here.
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atrophy1 2 and functional hyposplenism,3 and the main-
stay of GvHD treatment is immunosuppressive therapy. 
Infection is therefore an important complication of both 
autologous and allogeneic HSCT, and recipients are 
at high risk of morbidity and mortality from influenza 
viruses.4–6 Guidelines recommend that the seasonal inac-
tivated influenza vaccine (SIIV) is administered annually 
starting 4–6 months post-HSCT,7 8 including patients with 
GvHD.9 While the SIIV is recommended by 96% of UK 
National Health Service allogeneic HSCT programmes,8 
uptake rates of only 60%–70% in the first 2 years post-
HSCT have been reported among UK HSCT recipi-
ents.10 11 The majority of UK allogeneic HSCT recipients 
are referred to their general practitioner (GP) with only 
8% of UK adult allogeneic HSCT programmes offering 
vaccination services. SIIV efficacy of 65.4%–80% has 
been reported in HSCT recipients, although in small 
cohorts.12 13 In both the UK and USA, physicians’ famil-
iarity with current guidelines, and perception of GvHD 
as a contraindication to vaccination have been identified 
as factors limiting vaccine uptake rates.10 11 14 No studies 
to date have explored the patient factors that influ-
ence SIIV hesitancy or intention in an HSCT recipient 
population.
The health belief model (HBM) is a widely used 
framework for investigating psychosocial determi-
nants of health behaviours15 and is recognised as an 
important predictor of influenza vaccination uptake.16 
The HBM proposes that an individual’s engagement in 
a specific preventative health behaviour is predicated 
on the following constructs: (1) perceived susceptibility 
to the illness, (2) perceived likelihood of contracting 
the illness, (3) perceived seriousness of the illness, (4) 
perceived barriers to engaging in the health behaviour, 
(5) perceived benefits of the health behaviour, (6) cues 
to engage in the health behaviour such as advice from a 
healthcare practitioner and (7) self-efficacy or the individ-
ual’s perception of their capability to engage or succeed 
in the behaviour. Additional emotional constructs may 
modify the HBM. In particular, worry may modify the 
impact of perceived risk of illness; a patient may perceive 
themselves to be at risk, but unless this is something 
that worries them they may not engage in a preventative 
behaviour.17 Furthermore, anticipated regret of illness if 
a health behaviour is not performed is also recognised as 
a predictor of intent.18
The objective of this study was to explore the socio-
demographic factors, and the vaccine and vaccina-
tion-specific health-beliefs that are associated with SIIV 
intention among HSCT recipients, using a HBM modi-
fied with the additional emotional constructs given 
above (mHBM). A better understanding of such asso-
ciations may allow development of targeted strategies 
that address issues specific to this unique and complex 
patient group, with the aim of increasing influenza 
vaccine uptake rates.
PArtICIPAnts And methOds
Participants
Patients were screened by HSCT nurse specialists for 
study eligibility during routine outpatient appointments 
between June and September 2016. Participants were 
recruited from three study sites to reduce geographical 
bias. Eligible patients were aged 16 years or over and 
recipients of autologous or allogeneic HSCT for any 
disease indication, with no absolute contraindication to 
receiving the SIIV during the next influenza season, and 
having not received the SIIV since transplant.
study questionnaire and hbm
Participants completed a study-specific, 42-item, paper-
based questionnaire. The questionnaire was completed 
anonymously and returned in sealed envelopes, so partic-
ipants felt free to express their belief without influence 
from their healthcare team.
Questions scoped type of HSCT (autologous or allo-
geneic), disease indication, time from HSCT, pre-HSCT 
SIIV receipt and receipt of non-SIIV vaccines since HSCT. 
Sociodemographic questions established age, gender, 
ethnic background, educational attainment, relationship 
status and residential circumstances.
Intention to receive the SIIV during the 2016–2017 
influenza season was assessed by two statements phrased 
in the affirmative (I intend to receive the influenza 
vaccine next winter) and negative (I will choose not to 
receive the influenza vaccine next winter). Participants’ 
agreement with each statement was expressed on 5-point 
Likert scales ranging from strongly disagree to strongly 
agree. Twenty-four health belief statements were mapped 
to the mHBM with between 2 and 5 statements clustered 
around each construct (box 1). Statements pertaining to 
the cues to vaccination construct were phrased to explore 
perception of HSCT team and GP knowledge of SIIV in 
the context of HSCT. Participants’ perceived impact of 
a recommendation to receive the SIIV from their HSCT 
team or GP was explored. Statements about preferred 
vaccination location and ease of access to services were 
also included. Again, participants’ agreement with each 
statement was expressed on 5-point Likert scales ranging 
from strongly disagree to strongly agree.
statistical analysis
Statistical analysis was performed with IBM SPSS V.24. For 
the dependent variable vaccination intention, partici-
pants’ agreement scores were summed and dichotomised 
to a ‘high-intent’ group (intention score > neutral value) 
and a ‘low-intent’ group (intention score ≤ to the neutral 
value).
Categorical patient characteristics and sociodemo-
graphic factors are reported as frequencies and percent-
ages. Associations between these variables and SIIV 
intention was examined with Pearson’s χ2 test, and Fish-
er’s exact test when expected values were less than 5.
Internal scale reliability for each cluster of mHBM 
construct statements was assessed using Cronbach’s α. 
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A value of >0.6 was considered indicative of acceptable 
internal scale reliability.19 Scale reliability was acceptable 
for constructs 1–6 (box 1) and statement scores were 
summed to give total construct scores for each partici-
pant. Scale reliability was unacceptable for constructs 7–9 
(box 1); therefore, statements were analysed individually. 
All construct scores were analysed as continuous scales, 
with 0 representing a neutral response (neither agree 
nor disagree). Mean agreement scores for low-intent and 
high-intent groups are presented with 95% CIs.
Participants’ mean agreement scores for each mHBM 
construct were compared between SIIV intention groups 
using analysis of variance. Homogeneity of variances was 
confirmed with Levene’s statistic. HSCT team and GP 
cue scores within low-intent and high-intent groups were 
compared with a paired sample t-test.
The impact of sociodemographic variables and health 
belief constructs on seasonal influenza vaccination 
intention was examined with hierarchical binary logistic 
regression. Variables and constructs that were statistically 
significant in univariate analysis were included as sepa-
rate regression blocks. Statistically significant variables 
that improved the predictive value (p<0.05 for the regres-
sion block) were included in the final model.
The assumption of a linear relationship between each 
independent variable and log of the outcome variable 
was tested and confirmed using the Box-Tidwell proce-
dure.20 Multicollinearity across all constructs was assessed. 
No variance inflation factor was greater than 10, and the 
mean of values was acceptable at 1.92.21
There were 10 missing data points from 6 participants 
across the study. These were all responses to mHBM state-
ments from the high-intent group. Summed agreement 
scores were not calculated for that participant for the 
affected HBM construct only.
Patient and public involvement
The study questionnaire was developed with the involve-
ment of volunteers from the Anthony Nolan patients 
and families panel. Using an initial draft questionnaire, 
box 1 health belief statements grouped by construct with associated Cronbach’s Į value
health belief model construct (Cronbach’s Į)
 1. Susceptibility to seasonal inluenza (α=0.83)
 Ź Now I have had a stem cell transplant, I can catch seasonal inluenza more easily than other people my age.
 Ź Now I have had a stem cell transplant, I can catch seasonal inluenza more easily than before my transplant.
 2. Likelihood of catching seasonal inluenza (α=0.91)
 Ź My chances of catching seasonal inluenza next winter will be high if I do not receive the seasonal inluenza vaccine.
 Ź I am more likely than other people my age to catch seasonal inluenza next winter if I do not receive the seasonal inluenza vaccine.
 Ź Now I have had a stem cell transplant, it is more likely that I will catch seasonal inluenza next winter if I do not receive the seasonal inluenza vaccine.
 3. Severity of seasonal inluenza infection (α=0.91)
 Ź If I do not receive the seasonal inluenza vaccine and caught seasonal inluenza next winter this would be a serious illness for me.
 Ź If I do not receive the seasonal inluenza vaccine and caught seasonal inluenza next winter, this would have a negative impact on my recovery from 
my stem cell transplant.
 Ź If I do not receive the seasonal inluenza vaccine and caught seasonal inluenza next winter, I would become more unwell than other people my age.
 4. Barriers to vaccination (α=0.84)
 Ź I am worried about the side effects of the seasonal inluenza vaccine.
 Ź If I receive the seasonal inluenza vaccine next winter, it may make me feel unwell with inluenza or an inluenza-like illness.
 Ź If I receive the seasonal inluenza vaccine next winter, I am more likely to experience side effects than other people my age.
 Ź If I receive the seasonal inluenza vaccine next winter, it may have a negative impact on my recovery from my stem cell transplant.
 Ź Now I have had a stem cell transplant the seasonal inluenza vaccine may not work as well for me as it does for other people my age.
 5. Beneits of vaccination (α=0.66)
 Ź If I receive the seasonal inluenza vaccine next winter, it may help to prevent me from catching seasonal inluenza.
 Ź If I receive the seasonal inluenza vaccine next winter, it may help to prevent me from passing seasonal inluenza to other people around me.
 Ź If I receive the seasonal inluenza vaccine next winter, but still catch inluenza, it may help to prevent me from becoming seriously unwell.
 6. Cues to vaccination (α=0.76)
 Ź If my transplant team advised me to receive the seasonal inluenza vaccine next winter, I would deinitely have it.
 Ź If my general practitioner (GP) advised me to receive the seasonal inluenza vaccine next winter, I would deinitely have it.
 Ź My GP understands my condition enough to know if the seasonal inluenza vaccine is right for me.
 Ź My transplant team understand my condition enough to know if the seasonal inluenza vaccine is right for me.
 7. Worry (α=0.47)
 Ź If I receive the seasonal inluenza vaccine next winter, I will worry less about catching seasonal inluenza.
 Ź The thought of catching seasonal inluenza next winter worries me.
 8. Self-eficacy (α=0.29)
 Ź I have enough information and am able to decide whether the seasonal inluenza vaccine is right for me.
 Ź I would ind it easy to attend my GP surgery next winter to receive the seasonal inluenza vaccine.
 9. Anticipated regret (α=0.15)
 Ź I would regret it if I decided not to receive the seasonal inluenza vaccine next winter and became unwell with seasonal inluenza.
 Ź I would regret it if I decided to receive the seasonal inluenza vaccine next winter and became unwell with side effects.
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think-aloud sessions were conducted to ensure that the 
questionnaire was clear, easy to understand, that interpre-
tation of each question was as intended, and that answers 
were consistent with the question asked. Volunteers were 
also asked for their overall feedback on the study ques-
tionnaire. The revised questionnaire was then piloted 
with volunteer patients who were asked to complete the 
questionnaire, keeping note of the time taken and to 
highlight any questions that they had difficulty answering 
or otherwise found problematic. The questionnaires 
were all completed within 10 minutes and no partici-
pants reported difficulty or concerns about the questions. 
Results will be disseminated to study participants through 
their transplant teams, and made available to participants 
through open access publication.
results
Patient characteristics
Characteristics of 93 study participants are given in 
table 1. 78.5% were recipients of allogeneic HSCT and 
the most frequent disease indication was acute myeloid 
leukaemia (28.0%). The majority (68.6%) were within 
the first 6 months post-HSCT. 40.9% of participants had 
received the SIIV before HSCT, and 4.3% had received a 
non-influenza vaccine since HSCT. 52.7% of participants 
were male, and most (84.9%) were of a white ethnic 
group.
sIIV vaccination intention for 2016–2017 inluenza season
Seventy-one (76.3%) participants expressed high SIIV 
intent, while 22 (23.7%) expressed low SIIV intent.
sociodemographic and transplant variables
There was a statistically significant difference in SIIV 
intention between age groups (table 1). Rate of high 
intent was greatest in the 35–54 age group at 91.7%, and 
lowest at 53.3% in the 65+ age group. There was no statis-
tically significant difference in gender, ethnicity, educa-
tional background, living circumstance or relationship 
status between SIIV intention groups.
There was no difference in type of HSCT or disease indi-
cation between SIIV intention groups. 81.3% of partici-
pants answering within the first 0–6 months post-HSCT 
had high intent, compared with 70% in those answering 
at 6–12 months, and 55.6% among those answering at >12 
months from HSCT, however, this finding was not statisti-
cally significant. To determine whether there was a differ-
ence in health beliefs between participants at different 
time points post-HSCT, mean agreement scores for all 
constructs were compared. There was no difference in 
mean agreement scores between participants at 0–6 and 
6–12 and >12 months post-HSCT. There was no associa-
tion between SIIV intention and receipt of any non-in-
fluenza vaccine since HSCT. However, of those who had 
received the SIIV prior to HSCT 89.5% had high intent 
compared with 67.3% of those who had not.
Table 1 Characteristics of n=93 study participants
Characteristic, n=93 n (%)
High SIIV 
intent n (%) P values
Gender
  Male 49 (52.7) 40 (81.6)
  Female 44 (47.3) 31 (70.5) 0.23
Age group
  16–34 22 (23.7) 15 (68.2)
  35–54 36 (38.7) 33 (91.7)
  55–64 20 (21.5) 15 (75)
  65+ 15 (16.1) 8 (53.5) 0.02*
HSCT type
  Allogeneic 73 (78.5) 59 (80.8)
  Autologous 20 (21.5) 15 (75) 0.78
Disease indication
  Acute lymphoblastic 
leukaemia 11 (11.8) 8 (72.7)
  Acute myeloid 
leukaemia 26 (28.0) 20 (76.9)
  Aplastic anaemia 5 (5.4) 3 (60)
  Chronic myeloid 
leukaemia 5 (5.4) 5 (100)
  Hodgkin lymphoma 9 (9.7) 9 (88.9)
  Myelodysplastic 
syndrome 5 (5.4) 3 (60)
  Myeloibrosis 2 (2.2) 1 (50)
  Multiple myeloma 22 (23.7) 17 (77.3)
  Non-Hodgkin’s 
lymphoma 8 (8.6) 6 (75) 0.79
Months from HSCT
  0–6 64 (68.8) 52 (81.3)
  >6–12 20 (21.5) 14 (70)
  >12 9 (9.7) 5 (55.6) 0.18
SIIV before HSCT
  Yes 38 (40.9) 34 (89.5)
  No 55 (59.1) 37 (67.3) 0.01*
Any non-SIIV vaccine since 
HSCT
  Yes 4 (4.3) 4 (100)
  No 89 (95.7) 67 (75.3) 0.26
Ethnicity
  White 79 (84.9) 69 (77.2)
  Asian 8 (8.6) 7 (87.5)
  Black 3 (3.2) 2 (66.7)
  Mixed 2 (2.2) 1 (50)
  Other 1 (1.1) 0 (0) 0.32
Educational background
  Higher education 30 (32.3) 24 (80)
  Secondary education 49 (52.7) 40 (81.6)
  Other 3 (3.2) 2 (66.7)
Continued
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hbm constructs
In univariate analysis, comparing mean construct agree-
ment scores between SIIV intention groups, participants 
in the high-intent group perceived greater suscepti-
bility to influenza, a greater likelihood of contracting 
influenza and perceived influenza to be a more severe 
illness (table 2). They also perceived greater poten-
tial benefit from vaccination, and fewer barriers to 
vaccination. Although the two groups expressed similar 
levels of worry about catching influenza, participants in 
the high-intent group felt they would worry less about 
catching influenza if vaccinated compared with the 
low-intent group. They also expressed greater concern 
about anticipated regret if they caught influenza having 
not been vaccinated. Level of anticipated regret of 
experiencing side effects if vaccinated was similarly low 
across the two groups. Participants in the high-intent 
group felt more strongly that they had enough infor-
mation to make decisions about vaccination and that it 
would be easy to attend their general practice surgery 
for vaccination.
A multivariate regression model (table 3) was statisti-
cally significant when compared with a constant only 
model indicating that this set of variables and constructs 
distinguishes reliably between HSCT recipients who 
express low and high SIIV intent. There was a moderately 
strong relationship with 74.7% (Nagelkerke R2) of vari-
ation in vaccination intention explained by the overall 
model. GP and HSCT team cues to vaccination, self-ef-
ficacy and anticipated regret constructs did not signifi-
cantly improve predictive value and so were not included 
in the final model. Age and pre-HSCT SIIV vaccination 
receipt remained independent predictors of SIIV inten-
tion, with those aged >65 and those who had not received 
SIIV before HSCT more likely to be in the low-intent 
group. A greater perceived benefit of vaccination was the 
Characteristic, n=93 n (%)
High SIIV 
intent n (%) P values
  Prefer not to answer 11 (11.8) 5 (45.5) 0.07
Living circumstances
  Renting 25 (26.9) 33 (76)
  Home owner 54 (58.1) 43 (79.6)
  Other 10 (10.8) 7 (70)
  Prefer not to answer 4 (4.7) 2 (50) 0.56
Relationship status
  Single 23 (24.7) 18 (78.3)
  Married/cohabiting 56 (60.2) 45 (80.4)
  Divorced/separated 10 (10.8) 5 (50)
  Prefer not to answer 4 (4.4) 3 (75) 0.22
*Statistically signiicant (p<0.05).
HSCT, haematopoietic stem cell transplant; SIIV, seasonal 
inactivated inluenza vaccine.
Table 1 Continued 
Table 2 Mean agreement score values for health belief constructs for low and high SIIV intent groups
Health belief model construct Low SIIV intent (n=22) High SIIV intent (n=71) P values
  1. Susceptibility to seasonal inluenza 0.05 (−0.70 to 0.70) 2.09 (1.75 to 4.39) <0.001
  2. Likelihood of catching seasonal inluenza −0.45 (−1.39 to 0.40) 2.58 (2.00 to 3.18)* <0.001
  3. Severity of seasonal inluenza infection 0.77 (−0.17 to 1.72) 2.65 (2.09 to 3.23)* 0.002
  4. Barriers to vaccination 1.27 (0.11 to 2.44) −1.55 (−2.34 to −0.80)† 0.001
  5. Beneits of vaccination −0.05 (0.00 to 1.78) 2.56 (2.13 to 3.00) <0.001
  6. Cues to vaccination
  HSCT team understands my condition 1.14 (0.55 to 1.32) 1.63 (1.52 to 1.75) <0.001
  GP understands my condition −0.32 (0.83 to 0.13) 0.59 (0.55 to 0.83)‡ <0.001
  7. Worry
  About catching inluenza 0.14 (−0.43 to 0.71) 0.39 (0.17 to −0.63) 0.34
  Less about catching inluenza if vaccinated −0.23 (0.60 to 0.07) 0.80 (0.61 to 1.00) <0.001
  8. Self-eficacy
  Have enough information to decide about 
vaccination
0.14 (−0.32 to 0.58) 0.81 (0.61 to 1.00) 0.007
  Would ind it easy to attend GP for vaccination 0.32 (−0.12 to 1.72) 1.10 (1.89 to 2.00) <0.001
  9. Anticipated regret
  Of catching inluenza if not vaccinated 0.27 (−0.21 to 0.74) 1.35 (1.18 to 1.52) <0.001
  Of side effects if vaccinated −0.09 (−0.15 to 0.37) 0.13 (−0.12 to 0.39) 0.4
*n=69.
†n=68.
‡n=70.
GP,  general practitioner; HSCT, haematopoietic stem cell transplant; SIIV , seasonal inactivated inluenza vaccine. 
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strongest predictor of being in the high-intent group. 
Although the constructs susceptibility to influenza, likeli-
hood of contracting influenza, severity of influenza infec-
tion, barriers to vaccination and worry about catching 
influenza improved the predictive value of the overall 
multivariate model, they did not independently predict 
vaccination intention.
Cues to vaccination and preferred vaccination location
Considering their HSCT team and GPs, both high-in-
tent and low-intent groups agreed more strongly with 
statements that their HSCT team understands their 
condition enough to know if the influenza vaccine is 
right for them. Patients were also asked how much they 
agreed with the statement that they would definitely have 
the vaccine if their GP or HSCT team recommended it. 
Agreement scores were dichotomised to low agreement 
(≤neutral value) and high agreement (>neutral value). Of 
those 22 patients with low intent, 90% agreed that they 
would receive the vaccine if their HSCT team recom-
mended it, and only 22.7% if their GP recommended 
it, compared with 98.6% and 90.0%, respectively, in the 
high-intent group.
Participant responses to the statement I would prefer 
to have the seasonal influenza vaccine next winter at my 
transplant centre instead of my GP surgery were catego-
rised into prefers HSCT centre, prefers GP surgery or no 
preference. Of the low-intent group, over half (54.5%) 
favoured vaccination at their HSCT centre, with only 
a minority (4.5%) favouring vaccination at their GP 
surgery. Of those with high intent, 43.7% favoured vacci-
nation at their HSCT programme, compared with 29.6% 
at their GP surgery although these findings did not reach 
statistical significance (p=0.05).
dIsCussIOn
This is the first study to explore sociodemographic factors 
and psychological determinants of SIIV intention among 
HSCT recipients. Approximately, a quarter of partici-
pants expressed low SIIV intent which is in keeping with 
previously reported SIIV uptake rates of 60%–70%.10 11 
Participants’ SIIV uptake during the 2016–2017 UK influ-
enza season was not evaluated, and uptake in this cohort 
may not be equivalent to intent rates reported here.
Constructs of a mHBM were significant determinants 
of SIIV intention. Strategies tailored to a population and 
their specific concerns are the most effective at improving 
knowledge and changing attitudes towards vaccination, 
and increasing vaccine uptake.22 Based on our findings, 
the mHBM may provide a useful framework for struc-
turing strategies to address low SIIV intent in the HSCT 
population. Exploring HSCT recipients' increased risk 
of influenza, both in terms of susceptibility and severity, 
discussing the potential benefits of vaccination, and 
exploring concerns around side effects may help to 
promote vaccine intent and uptake.
A strong association between past vaccination 
behaviours and future vaccination intent has been 
reported.23 Previous influenza vaccination has been asso-
ciated with high-intent or uptake in all at-risk groups24 25 
and patients with cancer26 and our findings accord with 
this. It may therefore be helpful to explore recipients 
pre-HSCT SIIV behaviour and discussion rationale for 
refusal where appropriate.
It was reassuring to find that none of gender, ethnicity, 
educational background, living circumstances or rela-
tionship status were associated with vaccine hesitancy in 
this study. However, vaccination intention did vary with 
age. High intent was greatest at 91.7% in the 35–53 age 
bracket, but of concern, fell in those over 65%–53.5%, 
which is below the 2015–2016 uptake rate of 71% in 
the equivalent UK general population age group.27 
Older age has been reported as a barrier to vaccina-
tion in a cohort of oncology patients, including some 
with haematological malignancy.26 However, a French 
study of patients with secondary immunodeficiency, 
including haematological disorders, reported higher 
vaccination rates in those aged over 65 compared with 
younger patients.28 In a UK study, older age was found 
to be a predictor of uptake of the 2009 pandemic influ-
enza A vaccine among high-risk adults.29 A meta-analysis 
of international studies found inconsistent association 
between age and vaccination intent and uptake in the 
general public, older patients and those with chronic 
disease.23 It is not apparent from these studies why age 
impacts on intent, and there are likely to be a range of 
social, psychological, financial and healthcare access 
issues specific to each study population. Our findings 
highlight a specific age group in whom intent is low and 
Table 3 Multivariate logistic regression model predicting 
odds of high SIIV intent
Variable
OR of high SIIV 
intent (95% CI) P values
Age >65 0.02 (0.01 to 0.57) 0.02*
No SIIV before HSCT 0.04 (0.02 to 0.56) 0.02*
Beneits of vaccination 2.96 (1.29 to 6.81) 0.01*
Susceptibility to seasonal 
inluenza
0.96 (0.33 to 2.78) 0.64
Likelihood of catching 
seasonal inluenza
1.68 (0.86 to 3.26) 0.13
Severity of seasonal 
inluenza infection
0.69 (0.39 to 1.21) 0.20
Barriers to vaccination 0.69 (0.57 to 0.99) 0.05
Worry less about catching 
seasonal inluenza if 
vaccinated
4.99 (1.01 to 24.77) 0.05
Overall model was statistically signiicant compared with a 
constant only model (p<0.001).
*Statistically signiicant independent predictor (p<0.05).
HSCT, haematopoietic stem cell transplant; SIIV, seasonal 
inactivated inluenza vaccine. 
7Miller PDE, et al. BMJ Open 2018;8:e021222. doi:10.1136/bmjopen-2017-021222
Open access
may benefit from targeted intervention. Further evalua-
tion of this finding and exploration of underlying deter-
minants is warranted.
High SIIV intent was greatest in those recipients within 
the first 0–6 months post-HSCT (81.3%) and lowest at 
more than 12 months (55.6%) although this finding was 
not statistically significant. Longer time from HSCT may 
be associated with a change in perceived risk of infection, 
or concern about vaccine side effects or efficacy; however, 
we did not detect any statistically significant difference in 
health beliefs at 0–6, 6–12 and >12 months from HSCT. 
This finding suggests there is a need for reinforcement 
of SIIV intent from healthcare professionals throughout 
and beyond the first-year post-HSCT.
In both vaccine intention groups, patients expressed 
greater confidence in their HSCT team than their GP, 
with respect to understanding of whether the influ-
enza vaccine is right for them. Fewer patients felt that 
a recommendation from their GP would prompt them 
to receive the SIIV compared with if their HSCT team 
made the recommendation. This was most marked in the 
low-intent group. These findings suggest that cues from 
the HSCT team are important in promoting vaccination 
among HSCT recipients, and particularly for those with 
low intent. Cues from healthcare providers are consid-
ered a key factor in promoting vaccination23 and a study 
of Israeli patients with cancer identified recommendation 
from an oncologist as a significant predictor of vaccine 
uptake.26 Our findings accord with this, and suggest 
that HSCT recipients value the advice of their specialist 
team. This highlights the importance of HSCT special-
ists engaging in discussion with patients about influenza 
vaccination. Preference for vaccination at an HSCT 
centre rather than GP surgery was similar at 43.7% and 
54.5% in low-intent and high-intent groups, respectively. 
In the high-intent group, more patients expressed a pref-
erence for vaccination at their GP surgery than in the 
low-intent group. For approximately 50% of those HSCT 
recipients with both low and high intent, access to an 
SIIV service at HSCT centres may facilitate vaccination 
uptake.
None of the transplant variables assessed were associ-
ated with SIIV intention. Current influenza vaccination 
guidelines are standardised for all HSCT recipients as 
evidence is insufficient to recommend modification 
according to donor type, stem cell source or condi-
tioning.7 30 Influenza infections are reported to occur 
with higher frequency in allogeneic compared with 
autologous HSCT recipients31 32 and may have a higher 
associated morbidity and mortality33 although this latter 
finding has not been consistently reported.4 There was no 
difference in vaccination intention between autologous 
and allogeneic HSCT recipients. This suggests the unique 
aspects of allogeneic HSCT, principally GvHD and the 
need for immunosuppressive therapy, do not contribute 
to increased influenza vaccination intention in this group 
compared with autoHSCT recipients.
strength And weAknesses Of the study
Our study was developed from an established theoret-
ical framework for exploring health beliefs. Think-aloud 
sessions and a pilot exercise ensured that the question-
naire was easy to understand and acceptable to partici-
pants. By completing the questionnaire anonymously, 
participants were encouraged to respond according to 
their own beliefs without influence by their healthcare 
team. By recruiting from three study sites, we sought to 
capture the beliefs of participants with different experi-
ences of post-HSCT care, reduce the impact of geograph-
ical bias and render our results more generalisable to the 
UK HSCT population. The study did not include a qual-
itative component and there may be additional determi-
nants of influenza vaccine intention not captured here. 
Data on non-responders were not captured and therefore 
we cannot exclude a participation bias. The small abso-
lute number of participants expressing low SIIV intent in 
our study may bias our data.
COnClusIOn
Our data indicate that the constructs of a mHBM are 
important determinants of SIIV intention in the HSCT 
recipient population. These constructs may be used to 
develop interventions addressing low SIIV intent, for 
example, SIIV uptake among HSCT recipients may be 
promoted by public health authorities and patient support 
groups with messages adapted from our findings. Future 
prospective studies to investigate the efficacy of such inter-
vention are warranted. HSCT recipients strongly value 
the expertise and recommendation of their transplant 
team, and we would encourage practitioners to discuss 
SIIV intention with all patients as a routine and important 
aspect of post-transplant care. Furthermore, those aged 
over 65, and those who had not received the SIIV prior to 
HSCT were particularly likely to have low intent and may 
be target groups. Local provision of vaccination services 
at HSCT centres may serve as an additional promoter for 
a proportion of patients and this would require allocation 
of resources from health commissioners.
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